ACHR three-lens brief
Evidence-based stock research on ACHR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 14.5pp over 30 days. · Trading at 9% of its 52-week range — deep in the lower band.
- Trading at 9% of its 52-week range — deep in the lower band.
- Underperforming SPY by 14.5pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $10.94 — 92% above current (9 analysts).
- Negative free cash flow last quarterly (-$376.44M).
ACHR closed at $5.70 (-1.21%) as of 2026-04-25. Market cap: $4.27B. Positives: analyst mean target $10.94 — 92% above current (9 analysts).. Concerns: trading at 9% of its 52-week range — deep in the lower band.; underperforming SPY by 14.5pp over 30 days.. Last quarter: Revenue $300.0K, net income -$188.90M, free cash flow -$376.44M. Watching for: 2026-05-11 earnings release (16 days out).
Why three lenses on ACHR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACHRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ACHR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACHR brief"></iframe>